Immunotherapeutic Progress and Application of Bispecific Antibody in Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 7

PMID 36341333

Authors

Jingyue Kang

Tonglin Sun

Yan Zhang

Affiliations

Soon will be listed here.

Abstract

Bispecific antibodies (bsAbs) are artificial antibodies with two distinct antigen-binding sites that can bind to different antigens or different epitopes on the same antigen. Based on a variety of technology platforms currently developed, bsAbs can exhibit different formats and mechanisms of action. The upgrading of antibody technology has promoted the development of bsAbs, which has been effectively used in the treatment of tumors. So far, 7 bsAbs have been approved for marketing in the world, and more than 200 bsAbs are in clinical and preclinical research stages. Here, we summarize the development process of bsAbs, application in tumor treatment and look forward to the challenges in future development.

Citing Articles

Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.

Hushmandi K, Einollahi B, Lee E, Sakaizawa R, Glaviano A, Reiter R Int J Biol Sci. 2025; 21(4):1410-1435.

PMID: 39990653 PMC: 11844292. DOI: 10.7150/ijbs.96155.

Quantifying antibody binding: techniques and therapeutic implications.

Lodge J, Kajtar L, Duxbury R, Hall D, Burley G, Cordy J MAbs. 2025; 17(1):2459795.

PMID: 39957177 PMC: 11834528. DOI: 10.1080/19420862.2025.2459795.

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies.

Choi S, Lee J, Ko S, Hong S, Jin H Biomol Ther (Seoul). 2024; 32(6):708-722.

PMID: 39448393 PMC: 11535297. DOI: 10.4062/biomolther.2024.146.

Engineering and physicochemical characterization of a novel, stable, symmetric bispecific antibody with dual target-binding using a common light chain.

Saito S, Nakayama M, Yamazaki K, Miyamoto Y, Hiraishi K, Tomioka D Protein Sci. 2024; 33(10):e5121.

PMID: 39276019 PMC: 11401053. DOI: 10.1002/pro.5121.

Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.

Raja A, Kasana A, Verma V Mol Biotechnol. 2024; .

PMID: 39222285 DOI: 10.1007/s12033-024-01270-y.

References

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology. 1992; 24:524-6. View

Hofmann T, Krah S, Sellmann C, Zielonka S, Doerner A . Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies. Int J Mol Sci. 2020; 21(18). PMC: 7554978. DOI: 10.3390/ijms21186551. View

Kohnke T, Krupka C, Tischer J, Knosel T, Subklewe M . Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015; 8:111. PMC: 4599591. DOI: 10.1186/s13045-015-0213-6. View

Salvador J, Vilaplana L, Marco M . Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019; 411(9):1703-1713. DOI: 10.1007/s00216-019-01633-4. View

Chames P, Baty D . Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel. 2009; 12(2):276-83. View

Blair H . Emicizumab: A Review in Haemophilia A. Drugs. 2019; 79(15):1697-1707. DOI: 10.1007/s40265-019-01200-2. View

Carter P . Bispecific human IgG by design. J Immunol Methods. 2001; 248(1-2):7-15. DOI: 10.1016/s0022-1759(00)00339-2. View

Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T . Design and Production of Bispecific Antibodies. Antibodies (Basel). 2019; 8(3). PMC: 6783844. DOI: 10.3390/antib8030043. View

Klapper L, Glathe S, Vaisman N, Hynes N, ANDREWS G, Sela M . The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 1999; 96(9):4995-5000. PMC: 21805. DOI: 10.1073/pnas.96.9.4995. View

10.

Frogel M, Stewart D, Hoopes M, Fernandes A, Mahadevia P . A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010; 16(1):46-58. PMC: 10437841. DOI: 10.18553/jmcp.2010.16.1.46. View

11.

Durbin H, Young S, Stewart L, Wrba F, Rowan A, Snary D . An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci U S A. 1994; 91(10):4313-7. PMC: 43775. DOI: 10.1073/pnas.91.10.4313. View

12.

Ishii N, Takahashi T, Soroosh P, Sugamura K . OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol. 2010; 105:63-98. DOI: 10.1016/S0065-2776(10)05003-0. View

13.

Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K . Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020; 10(8):1194-1209. DOI: 10.1158/2159-8290.CD-20-0116. View

14.

Demarest S, Glaser S . Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel. 2008; 11(5):675-87. View

15.

Wu J, Fu J, Zhang M, Liu D . AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015; 8:96. PMC: 4522136. DOI: 10.1186/s13045-015-0188-3. View

16.

Kontermann R . Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009; 23(2):93-109. DOI: 10.2165/00063030-200923020-00003. View

17.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

18.

Yuraszeck T, Kasichayanula S, Benjamin J . Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. Clin Pharmacol Ther. 2017; 101(5):634-645. PMC: 5763312. DOI: 10.1002/cpt.651. View

19.

Conaghan P, Ashraf S, Tytherleigh M, Wilding J, Tchilian E, Bicknell D . Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br J Cancer. 2008; 98(7):1217-25. PMC: 2359646. DOI: 10.1038/sj.bjc.6604289. View

20.

Dulak A, Gubish C, Stabile L, Henry C, Siegfried J . HGF-independent potentiation of EGFR action by c-Met. Oncogene. 2011; 30(33):3625-35. PMC: 3126872. DOI: 10.1038/onc.2011.84. View